Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Paul Martin, MD
Fred Hutchinson Cancer Center
Principal Investigator - Shih-Yao Lin, MD, PhD
AltruBio, Inc. (formerly AbGenomics International)
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- David Geffen School of Medicine at Ucla
Los Angeles, California, United States
- University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Emory University
Atlanta, Georgia, United States
- University of Chicago
Chicago, Illinois, United States
- the University of Kansas Cancer Center
Westwood, Kansas, United States
- Dana Farber Cancer Center
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
- Baylor College of Medicine-Houston Methodist & Texas Children'S Hospital
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2018
- Primary completion
- 30 Sept 2022
- Completion
- 31 Dec 2022
- Last update posted
- 19 Jan 2023
- Registered enrollment
- 37
- Registry id
- NCT03327857
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.